Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EWTX Edgewise Therapeutics	$13.39 +3.1%	$13.96	$10.60 ▼ $38.12	$1.37B	0.26	604,758 shs	939,082 shs
GTHX G1 Therapeutics	$7.15	$7.13	$1.08 ▼ $7.19	$373.81M	1.66	1.70 million shs	N/A
JANX Janux Therapeutics	$24.27 +7.1%	$24.63	$21.97 ▼ $71.71	$1.36B	2.86	882,815 shs	554,422 shs
SPRY ARS Pharmaceuticals	$16.66 +1.7%	$16.79	$10.00 ▼ $18.90	$1.61B	0.9	1.24 million shs	2.08 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EWTX Edgewise Therapeutics	+2.44%	-4.56%	-6.14%	-12.76%	-21.03%
GTHX G1 Therapeutics	0.00%	0.00%	0.00%	0.00%	+0.85%
JANX Janux Therapeutics	-0.70%	-5.19%	-9.86%	-10.50%	-36.78%
SPRY ARS Pharmaceuticals	-6.40%	-5.75%	-7.41%	+22.70%	+50.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EWTX Edgewise Therapeutics	1.9592 of 5 stars	3.5	2.0	0.0	0.0	2.4	1.7	0.0
GTHX G1 Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	2.6526 of 5 stars	3.5	2.0	0.0	0.0	2.8	3.3	0.0
SPRY ARS Pharmaceuticals	3.4327 of 5 stars	3.6	2.0	0.0	0.0	3.5	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EWTX Edgewise Therapeutics	2.90	Moderate Buy	$41.60	210.68% Upside
GTHX G1 Therapeutics	0.00	N/A	N/A	N/A
JANX Janux Therapeutics	3.08	Buy	$91.89	278.61% Upside
SPRY ARS Pharmaceuticals	3.17	Buy	$31.00	86.07% Upside

Current Analyst Ratings Breakdown

Latest GTHX, EWTX, JANX, and SPRY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	EWTX Edgewise Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$48.00 ➝ $49.00
7/30/2025	EWTX Edgewise Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy	$46.00
7/11/2025	JANX Janux Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
6/30/2025	EWTX Edgewise Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$42.00
6/5/2025	EWTX Edgewise Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$48.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$5.59 per share	N/A
GTHX G1 Therapeutics	$58.20M	6.42	N/A	N/A	$0.68 per share	10.51
JANX Janux Therapeutics	$10.59M	137.71	N/A	N/A	$16.48 per share	1.47
SPRY ARS Pharmaceuticals	$89.15M	18.35	$0.01 per share	1,934.27	$2.64 per share	6.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EWTX Edgewise Therapeutics	-$133.81M	-$1.55	N/A	N/A	N/A	N/A	-30.65%	-29.18%	8/14/2025 (Estimated)
GTHX G1 Therapeutics	-$47.97M	-$0.62	N/A	N/A	N/A	-76.93%	-136.98%	-39.33%	N/A
JANX Janux Therapeutics	-$68.99M	-$1.80	N/A	N/A	N/A	N/A	-11.48%	-11.01%	N/A
SPRY ARS Pharmaceuticals	$8M	-$0.16	N/A	N/A	N/A	-16.11%	-6.94%	-5.60%	8/13/2025 (Estimated)

Latest GTHX, EWTX, JANX, and SPRY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	SPRY ARS Pharmaceuticals	-$0.42	N/A	N/A	N/A	$12.92 million	N/A
8/7/2025	Q2 2025	EWTX Edgewise Therapeutics	-$0.42	-$0.34	+$0.08	-$0.34	N/A	N/A
8/7/2025	Q2 2025	JANX Janux Therapeutics	-$0.48	-$0.55	-$0.07	-$0.55	$0.30 million	N/A
5/14/2025	Q1 2025	SPRY ARS Pharmaceuticals	-$0.35	-$0.35	N/A	-$0.35	$7.48 million	$7.97 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
GTHX G1 Therapeutics	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EWTX Edgewise Therapeutics	N/A	28.87	20.99
GTHX G1 Therapeutics	1.34	2.48	2.12
JANX Janux Therapeutics	N/A	47.03	47.03
SPRY ARS Pharmaceuticals	0.30	11.00	10.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EWTX Edgewise Therapeutics	N/A
GTHX G1 Therapeutics	24.21%
JANX Janux Therapeutics	75.39%
SPRY ARS Pharmaceuticals	68.16%

Insider Ownership

Company	Insider Ownership
EWTX Edgewise Therapeutics	23.20%
GTHX G1 Therapeutics	6.11%
JANX Janux Therapeutics	29.40%
SPRY ARS Pharmaceuticals	33.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EWTX Edgewise Therapeutics	60	105.35 million	80.91 million	Optionable
GTHX G1 Therapeutics	170	52.28 million	49.09 million	Optionable
JANX Janux Therapeutics	30	60.09 million	42.43 million	Optionable
SPRY ARS Pharmaceuticals	90	98.21 million	65.31 million	Optionable

GTHX, EWTX, JANX, and SPRY Headlines

Recent News About These Companies

Earnings Outlook For ARS Pharmaceuticals

4 hours ago | benzinga.com

ARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 6.3% - Should You Sell?

August 12 at 4:58 PM | marketbeat.com

Analysts Set ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) PT at $31.00

August 8, 2025 | americanbankingnews.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Holdings Raised by Levin Capital Strategies L.P.

August 6, 2025 | marketbeat.com

XTX Topco Ltd Raises Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

August 6, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of "Buy" by Brokerages

August 5, 2025 | marketbeat.com

Here's What Could Help ARS Pharmaceuticals, Inc. (SPRY) Maintain Its Recent Price Strength

August 4, 2025 | msn.com

ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results

August 4, 2025 | globenewswire.com

14,780 Shares in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Acquired by Foster & Motley Inc.

August 3, 2025 | marketbeat.com

ARS Pharmaceuticals (SPRY) Expected to Announce Quarterly Earnings on Tuesday

July 30, 2025 | marketbeat.com

Analysts Estimate ARS Pharmaceuticals, Inc. (SPRY) to Report a Decline in Earnings: What to Look Out for

July 29, 2025 | zacks.com

Schulhoff & Co. Inc. Purchases Shares of 40,500 ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

July 28, 2025 | marketbeat.com

Knights of Columbus Asset Advisors LLC Invests $543,000 in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

July 27, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Position Lowered by Royce & Associates LP

July 27, 2025 | marketbeat.com

ARS Pharmaceuticals (NASDAQ:SPRY) Downgraded to Sell Rating by Wall Street Zen

July 26, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Purchased by Legato Capital Management LLC

July 24, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Bought by FAS Wealth Partners Inc.

July 19, 2025 | marketbeat.com

EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

July 18, 2025 | globenewswire.com

What Makes ARS Pharmaceuticals, Inc. (SPRY) a Good Fit for 'Trend Investing'

July 15, 2025 | sharewise.comS

ARS Pharmaceuticals, Inc. (SPRY) is a Great Momentum Stock: Should You Buy?

July 15, 2025 | zacks.com

Wall Street Analysts See a 78.77% Upside in ARS Pharmaceuticals, Inc. (SPRY): Can the Stock Really Move This High?

July 15, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GTHX, EWTX, JANX, and SPRY Company Descriptions

Edgewise Therapeutics NASDAQ:EWTX

$13.39 +0.40 (+3.08%)

Closing price 04:00 PM Eastern

Extended Trading

$13.56 +0.16 (+1.23%)

As of 07:30 PM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

G1 Therapeutics NASDAQ:GTHX

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Janux Therapeutics NASDAQ:JANX

$24.27 +1.60 (+7.06%)

Closing price 04:00 PM Eastern

Extended Trading

$24.36 +0.09 (+0.37%)

As of 06:53 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

ARS Pharmaceuticals NASDAQ:SPRY

$16.66 +0.28 (+1.71%)

Closing price 04:00 PM Eastern

Extended Trading

$16.99 +0.33 (+1.98%)

As of 07:59 PM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time